Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human SNRPE Antibodies:
anti-Mouse (Murine) SNRPE Antibodies:
Go to our pre-filtered search.
Human Polyclonal SNRPE Primary Antibody for IHC, IHC (p) - ABIN4282574
Beltran-Sastre, Benisty, Burnier, Berger, Serrano, Kiel: Tuneable endogenous mammalian target complementation via multiplexed plasmid-based recombineering. in Scientific reports 2015
genetic association/nutrigenomic studies in population in Seoul, Republic of Korea: Data suggest that (1) relatively low iodine intake and (2) more than excessive iodine intake are significant risk factors for occurrence of BRAF (show BRAF Antibodies) mutations in thyroid gland and may be risk factors for development of PTC (show F9 Antibodies) (papillary thyroid cancer) in iodine-replete area.
The BRAF (show BRAF Antibodies) gene has been reported to be mutated in some human cancers. The BRAF (show BRAF Antibodies) mutations have been implicated in ameloblastoma.
Children with Langerhans cell histiocytosis (LCH) tend to have a high overall survival rate and a high incidence rate of BRAF (show BRAF Antibodies)-V600E mutation.
BRAF (show BRAF Antibodies) mutations more frequently affected individuals younger than 61 with phototype II. In contrast, NRAS (show NRAS Antibodies) mutations were more frequent in phototype III cases. Mutations of both genes were more frequent in cases with satellitosis in the first melanoma, and in cases with ulceration in the subsequent lesions.
Identification of KRAS/NRAS/BRAF (show BRAF Antibodies) mutation status is crucial to predict the therapeutic effect and determine individual therapeutic strategies for patients with colorectal cancer.
we did not observe GNAS (show GNAS Antibodies) or BRAF (show BRAF Antibodies) mutations in urachal adenocarcinomas
Study finds infrequent BRAF (show BRAF Antibodies) alterations but enriched FGFR (show FGFR2 Antibodies) alterations in adults as compared with that reported in pediatric pilocytic astrocytomas. In addition, coexistent BRAF (show BRAF Antibodies) and FGFR (show FGFR2 Antibodies) alterations and a significant association of FGFR (show FGFR2 Antibodies) alterations with age and tumor location were noted.
a low frequency of BRAF or KRAS mutation in Chinese patients with low-grade serous carcinoma of the ovary
genetic association studies in population in China: Data suggest that, in patients with unilateral papillary thyroid carcinoma, a mutation in BRAF (show BRAF Antibodies) (V600E) plus multi-focality are both independently and synergically associated with CLNM (central lymph node metastasis) in the population studied.
RHEB (show RHEB Antibodies) Y35N expressing cells undergo cancer transformation due to decreased interaction between RHEB (show RHEB Antibodies) and BRAF (show BRAF Antibodies) resulting in overactive RAF (show RAF1 Antibodies)/MEK (show MAP2K1 Antibodies)/ERK (show EPHB2 Antibodies) signaling. Taken together with the previously established function of RHEB (show RHEB Antibodies) to activate mTORC1 signaling, it appears that RHEB (show RHEB Antibodies) performs a dual function; one is to suppress the RAF (show RAF1 Antibodies)/MEK (show MAP2K1 Antibodies)/ERK (show EPHB2 Antibodies) signaling and the other is to activate mTORC1 signaling.
mosaic expression of BRAF (show BRAF Antibodies)(V600E) in mouse erythro-myeloid progenitors results in clonal expansion of tissue-resident macrophages and a severe late-onset neurodegenerative disorder
CDX2 (show CDX2 Antibodies)(Null)/BRAF (show BRAF Antibodies)(V600E) expression in adult mouse intestinal epithelium led to serrated morphology tumors (including carcinomas) and BRAF (show BRAF Antibodies)(V600E) potently interacted with CDX2 (show CDX2 Antibodies) silencing to alter gene expression. Like human serrated lesions, CDX2 (show CDX2 Antibodies)(Null)/BRAF (show BRAF Antibodies)(V600E)-mutant epithelium expressed gastric markers.
expression of an endogenous Braf (show BRAF Antibodies)(D631A) kinase-inactive isoform in mice (corresponding to the human BRAF (show BRAF Antibodies)(D594A) mutation) triggers lung adenocarcinoma in vivo, indicating that BRAF (show BRAF Antibodies)-inactivating mutations are initiating events in lung oncogenesis
TTM (show SLITRK1 Antibodies) reduces copper levels and MAPK (show MAPK1 Antibodies) signaling, thereby inhibiting BRAF (show BRAF Antibodies)(V600E)-driven melanoma tumor growth.
BRAF (show BRAF Antibodies) and ROKalpha (show ROCK2 Antibodies) form independent RAF1 (show RAF1 Antibodies) complexes in embryonic fibroblasts (MEFs) treated with epidermal growth factor (EGF (show EGF Antibodies)).
Braf (show BRAF Antibodies)(V600E) expression, coupled with simultaneous p53 (show TP53 Antibodies) ablation, permits bypass of senescence and progression to lung adenocarcinoma.
These results provide support for the role of BRAF (show BRAF Antibodies)(V600E) in metastasis.
Mechanistically, BRAF (show BRAF Antibodies) and RAF1 (show RAF1 Antibodies) operate independently to balance MAPK (show MAPK1 Antibodies) signaling: BRAF (show BRAF Antibodies) promotes ERK (show EPHB2 Antibodies) activation, while RAF1 (show RAF1 Antibodies) dims stress kinase activation.
Mass spectrometry based screening for potential interaction partners revealed that BRAF (show BRAF Antibodies) interacts and phosphorylates PAX3 (show PAX3 Antibodies).
Using a conditional allele for Braf (show BRAF Antibodies)(V600E) , a mutation observed in clinical cases of GIST, authors observed that Braf (show BRAF Antibodies)(V600E) activation was sufficient to drive ICC hyperplasia but not GIST tumorigenesis.
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene.
94 kDa B-raf protein
, B-Raf proto-oncogene serine/threonine-protein kinase (p94)
, murine sarcoma viral (v-raf) oncogene homolog B1
, proto-oncogene B-Raf
, serine/threonine-protein kinase B-raf
, v-raf murine sarcoma viral oncogene homolog B1
, sm protein E
, small nuclear ribonucleoprotein E
, small nuclear ribonucleoprotein polypeptide E
, SmE protein